Clinical Practice: Polymyalgia Rheumatica

Why It Matters

Effective PMR management reduces long‑term steroid toxicity and improves functional outcomes for an aging population, directly impacting healthcare costs and patient quality of life.

Key Takeaways

• PMR primarily affects patients over 50
• Glucocorticoids remain first‑line treatment
• Relapse rates approach 50% within two years
• Methotrexate and tocilizumab reduce steroid exposure
• Early diagnosis prevents irreversible joint damage

Pulse Analysis

Polymyalgia rheumatica is one of the most prevalent inflammatory disorders in older adults, affecting roughly 0.5% of individuals over age 50 in the United States. The condition presents with proximal muscle stiffness, morning pain, and elevated inflammatory markers, yet lacks a definitive laboratory test, making clinical acumen essential. Recent epidemiologic data highlight a rising burden as the population ages, prompting clinicians to refine diagnostic pathways that differentiate PMR from mimics such as rheumatoid arthritis or late‑onset lupus.

Glucocorticoids have long been the cornerstone of PMR therapy, typically initiated at 15‑20 mg of prednisone daily and tapered over 12‑18 months. While this regimen rapidly alleviates symptoms, up to half of patients experience relapse during tapering, and prolonged exposure raises risks of osteoporosis, diabetes, and infection. Consequently, the article underscores the growing role of glucocorticoid‑sparing agents. Low‑dose methotrexate, administered weekly, has demonstrated modest reductions in cumulative steroid dose, whereas interleukin‑6 inhibitors like tocilizumab show promise in refractory cases, offering faster tapering and fewer adverse events.

The broader implications extend beyond individual patient care. By integrating steroid‑sparing strategies, healthcare systems can curb the long‑term costs associated with glucocorticoid complications, a significant concern given the aging demographic. Moreover, early, accurate diagnosis coupled with personalized treatment algorithms aligns with value‑based care initiatives, ensuring that older adults maintain mobility and independence. As research progresses, biomarkers and imaging may soon augment clinical criteria, further streamlining PMR management and solidifying its place in modern geriatric rheumatology.

Original Description

A new Clinical Practice article summarizes the diagnosis and management of polymyalgia rheumatica in adults older than 50 years of age, emphasizing clinical diagnosis, glucocorticoids as first-line therapy, relapses, and glucocorticoid-sparing options.

Read “Polymyalgia Rheumatica” at NEJM.org.

#rheumatology #geriatrics #nejm